Compare Goodyear Tire & Rubber Co (GT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goodyear Tire & Rubber Co vs Recursion Pharmaceuticals Inc — how do they compare? Goodyear Tire & Rubber Co trades at $4.71 (market cap $1.37B), while Recursion Pharmaceuticals Inc trades at $3.93 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Goodyear Tire & Rubber Co for 57 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| GT | RXRX | |
|---|---|---|
Market Cap | $1.37B | $2.14B |
Volume | 9,470,773 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $10.54 | $6.79 |
52-Week Low | $4.66 | $2.84 |
Typical Hold Time | 57 Days | 22 Days |
Enterprise Value | $8.72B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goodyear Tire & Rubber (GT) trades at $4.69, up 0.64% on the day, but remains near 52-week lows amid a bearish technical outlook. The company reported a Q2 2026 loss of $0.61 per share, beating estimates but reflecting ongoing volume pressures. Revenue has declined from $20.8B in 2022 to $18.3B in 2025, with a net income margin of -14.37% in the latest period. Despite a low P/E of 4.69 and P/B of 0.48, negative ROE and ROA highlight profitability challenges. Recent news highlights a restructuring plan targeting margin improvement and debt reduction.
The outlook is mixed, with a consensus price target of $8.00 suggesting significant upside if restructuring succeeds. However, risks include persistent volume declines, high debt levels, and execution uncertainty. Analyst sentiment is cautious with 34.62% buy ratings, 50% hold, and 15.38% sell. Investors should weigh the deep value metrics against fundamental headwinds in the competitive tire industry.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
